Lorem has created the largest safety database of nano-rare patients treated that includes more than 50 nano-rare patients treated with bespoke ASO medicines discovered and developed at n-Lorem, more ...
SAN FRANCISCO, CALIFORNIA, Oct. 08, 2025 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics ...
Imugene Ltd (ASX:IMU, OTC:IUGNF, FRA:ILA) has dosed the first patient in the Bruton Tyrosine Kinase inhibitor (BTKi) ...
Background Marfan syndrome (MFS) is associated with progressive aortic and valvular disease requiring cardiac surgery, but ...
Participants in Cohort 1 have progressed to the open-label, Phase 2 portion of ELEVATE-45-201 ---- Company on track to report ELEVATE-45-201 ...
Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers through ...
Neurizon Therapeutics will increase its total patient cohort in Regimen I of the ALS Platform Trial from 160 to 240, with ...
June 2 () - Legend Biotech's experimental therapy showed early signs that its approach of generating disease-fighting cells ...
"To our knowledge, the VA-ADPKD cohort (12,217 patients with ADPKD) is currently the largest ADPKD patient cohort with sufficient clinical data to support potential predictive modeling of key ADPKD ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results